OHL nanoparticles (Optimum)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameOHL nanoparticles (Optimum)
Drug Alias Name3-oxododecanoyl homoserine lactone nanoparticles (Optimum)
ClassificationSmall molecules > Peptidomimetic
Mechanisms of ActionThymidylate synthase inhibitorsTubulin inhibitors
TargetsTubulinThymidylate synthase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOptimum Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOptimum Therapeutics Llc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A